Item 5.07. Submission of Matters to a Vote of Security Holders.
1. The election of six nominees to the Company's Board of Directors to serve until the 2021 annual meeting of stockholders. The nominees for election wereFrank Litvack , M.D., Linda Marbán, Ph.D.,David B. Musket ,George W. Dunbar , Jr.,Louis Manzo andEarl M. (Duke) Collier , Jr.; 2. The ratification of the appointment by the Audit Committee of the Company's Board of Directors ofRose, Snyder & Jacobs LLP as the Company's independent registered public accounting firm for the fiscal year endingDecember 31, 2020 ; 3. To approve the adoption of theCapricor Therapeutics 2020 Equity Incentive Plan; 4. To approve, by non-binding advisory vote, the resolution approving named executive officer compensation; and 5. To approve, by non-binding advisory vote, the frequency of future non-binding advisory votes on resolutions approving named executive officer compensation.
The final results of the matters voted on at the Annual Meeting, based on the presence in person or by proxy of holders of record of 7,778,818 shares of the 12,464,006 shares of the Company's common stock entitled to vote, were as follows:
1. Each of Dr. Litvack, Dr. Marbán, and Messrs. Musket, Dunbar, Manzo, and Collier were elected as directors of the Company to serve until the 2021 annual meeting of stockholders, and until his or her successor is elected, or until his or her earlier death, resignation or removal, as follows: FOR WITHHELD BROKER NON-VOTES Frank Litvack, M.D. 1,994,731 35,877 5,748,210 Linda Marbán, Ph.D. 2,004,415 26,193 5,748,210 David B. Musket 1,856,651 173,957 5,748,210 George W. Dunbar, Jr. 1,858,096 172,512 5,748,210 Louis Manzo 1,857,775 172,833 5,748,210 Earl M. (Duke) Collier, Jr. 2,010,868 19,740 5,748,210 2. The appointment by the Audit Committee of the Company's Board of Directors ofRose, Snyder & Jacobs LLP as the Company's independent registered public accounting firm for the fiscal year endingDecember 31, 2020 was ratified as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 7,616,245 29,998 132,575 0 3. The adoption of the Capricor Therapeutics 2020 Equity Incentive Plan was approved as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 1,766,874 213,632 50,102 5,748,210 4. The compensation of the Company's named executive officers was approved, on a non-binding advisory basis, as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 1,796,613 188,929 45,006 5,748,210 5. The preferred frequency, on a non-binding advisory basis, of future non-binding advisory votes to approve the compensation of the Company's named executive offices was "1 Year" as follows: THREE YEARS TWO YEARS ONE YEAR ABSTAIN BROKER NON-VOTES 347,621 74,466 1,570,885 37,636 5,748,210
© Edgar Online, source